Unknown PHASE3 INTERVENTIONAL 2-arm NCT00553423

Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage

Randomized Double Blind Placebo Controlled Trial of Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage

Sponsor: Aga Khan University

Conditions Encephalopathy, Hepatic Encephalopathy, Hepatocerebral Hepatocerebral Encephalopathy Portal-Systemic Encephalopathy

Interventions Lactulose Placebo

Updated 4 times since 2017 Last updated: Nov 2, 2007 Started: Nov 30, 2007 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Encephalopathy, Hepatic and Encephalopathy, Hepatocerebral, this trial is ongoing. The trial is conducted by Aga Khan University and has accumulated 4 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE3

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aga Khan University

Data source: Aga Khan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Karachi, Pakistan